Zurueck zur Suche

Reporte zur Charge 3N3GH

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

7Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
CA 4 VA 1 TX 1 MD 1

VAERS 1810134

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 3N3GH

schwer
Staat
CA
Alter
-
Geschlecht
F
Eingang
23.10.2021
Impfdatum
13.10.2021
Beginn
01.10.2021
Tage bis Beginn
-
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Blister Burning sensation Electric shock sensation Herpes zoster reactivation Inappropriate schedule of product administration Pain Paraesthesia Pruritus Rash papular Rash pruritic Rash vesicular Swelling Vaccination failure

Symptomtext

"Reactivation" of this virus; Vesicles with clear fluid like chickenpox; Vesicles with clear fluid/looks to me like chickenpox; Reddish bumps on my left wrist at first with itching/ along my waistline then from trunk to left arm and under both breasts; Reddish bumps on back of neck; Intense electric-like pinpricks; Burning; Burning with continued severe itching/ pain coupled with itching/ intolerable; 1st dose on 10th June 2020 and 2nd dose on 8th October 2021; Itching remains intense at times; Pain became really severe, intolerable/the pain came back with a vengeance; This case was reported by a nurse and described the occurrence of herpes zoster reactivation in a 73-year-old female patient who received Herpes zoster (Shingrix) (batch number 75XA2, expiry date unknown) and (batch number 3N3GH, expiry date unknown) for prophylaxis. Co-suspect products included valaciclovir hydrochloride (Valtrex) tablet for prophylaxis. The patient's past medical history included chickenpox (had severe chickenpox in 1956) and shingles (had 2 episodes of shingles in the late 1980, those were very typical with along nerve path clustering ( waistline area)). Previously administered products included Shingrix with an associated reaction of no adverse event (patient received first Shingrix dose on 10th June 2020). Concurrent medical conditions included fibromyalgia (had long term history), ulcerative colitis (had long term history), arthritis (had long term history) and breast cancer (had long term history). Concomitant products included fentanyl (Fentanyl Patch). On 8th October 2021, the patient received Shingrix .5 ml. On an unknown date, the dose was .5 ml. On 13th October 2021, the patient started Valtrex (oral) 500 mg 3 times daily (1500 mg daily). On 8th October 2021, unknown after receiving Shingrix and not applicable after starting Valtrex, the patient experienced drug dose administration interval too long. On 10th October 2021, the patient experienced herpes zoster reactivation, vesicles, varicella-like rash, itchy rash, erythropapular rash, tingling, burning sensation and pruritus. In October 2021, the patient experienced pain and lack of drug effect. The patient was treated with calamine + pramocaine hydrochloride (Caladryl Lotion), non-drug therapy (Ice Pack (No Medication)) and paracetamol (Tylenol). The action taken with Valtrex was unknown. On an unknown date, the outcome of the herpes zoster reactivation, varicella-like rash, itchy rash, erythropapular rash, tingling, burning sensation, lack of drug effect and drug dose administration interval too long were unknown and the outcome of the vesicles was recovering/resolving and the outcome of the pain and pruritus were not recovered/not resolved. The reporter considered the herpes zoster reactivation, vesicles, varicella-like rash, itchy rash, erythropapular rash, pain, tingling, burning sensation and pruritus to be related to Shingrix. It was unknown if the reporter considered the pruritus to be related to Valtrex. Additional details were provided as follows: The reporter was the patient herself. The reporter was a retired nurse. The patient received Shingrix in the left deltoid and about 10th October 2021, she found 1 then 2 reddish bumps on her left wrist at first with itching. Over the course of the next 24 hours, many more appeared along the waistline then from trunk to left arm and back of neck; also under both breasts. Concurrently, pain had started and became really severe, intense electric-like pinpricks and burning with continued severe itching. There were no eruptions on face, hands or feet. There was no reaction at the injection site; also no fever , shortness of breath or allergy-like other symptoms. The patient described that she had vesicles with clear fluid ( which looked like chickenpox to her) The patient took Caladryl lotion and then ice packs that helped control the pain somewhat. There was no effect on the pain with twice medication of Tylenol. This went on for the next 24 hours and the patient was able to get an appointment for evaluation on 13th October 2021 with an MD. The patient was evaluated and Rx for Valtrex tablets of 500mg thrice a day for 7 days was provided, which led to off label dosing frequency. The patient refused pain medication as she had a chronic condition controlled with a Fentanyl 12mcg patch and she was sure that it also helped controlling the pain of the outbreak to some extent. The patient received the first Shingrix dose on 10 June 2020, more than a year ago, which led to drug dose administration interval too long for the second dose. The patient did not experience any reaction and no unexpected untoward reaction to any other vaccines for the 1st dose. The patient did not have further pain at the time of reporting but the itching remained intense at times, which led to lack of drug effect for Valtrex. Several vesicles had dried and no new outbreak was noted over last 12 hours from the time of reporting. The patient had attached 3 pictures which she took for documentation. The patient was reporting it as she did not find any documentation listing such reaction as a possibility (common or uncommon). The patient further provided information that the pain came back with a vengeance and coupled with the itching, making it quite intolerable. The reporter stated that, based on her life in science, she was baffled that a vaccine which was aimed at preventing, was evidently causing a reactivation of the virus. The reporter was asking if there was any scientist in the organization who could answer this puzzling question.; Sender's Comments: US-GLAXOSMITHKLINE-US2021AMR214491:Same reporter, same patient, same suspect, different dose

Weitere VAERSDATA-Felder
Praegender Schweregrund
Electric shock sensation
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
Medical History/Concurrent Conditions: Arthritis (had long term history); Breast cancer (had long term history); Chickenpox (had severe chickenpox in 1956); Fibromyalgia (had long term history); Shingles (had 2 episodes of shingles in the late 1980, those were very typical with along nerve path clustering ( waistline area)); Ulcerative colitis (had long term history)
Andere Medikamente
FENTANYL PATCH; Valtrex
Allergien
-
Vorherige Impfungen
-

VAERS 2334907

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 3N3GH

gering
Staat
VA
Alter
68,0
Geschlecht
F
Eingang
25.06.2022
Impfdatum
21.06.2022
Beginn
21.06.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered Product preparation issue

Symptomtext

receiving only the AS01B adjuvant; receiving only the AS01B adjuvant; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 68-year-old female patient who received Herpes zoster (Shingrix) (batch number 3N3GH, expiry date 28th January 2023) for prophylaxis. On 21st June 2022, the patient received Shingrix. On 21st June 2022, unknown after receiving Shingrix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. Additional Information: GSK receipt date: 21-JUN-2022 Reporter's comment: The patient was administrated only the AS01B adjuvant of Shingrix. It was administered prior to reconstitution. The reporter was consented to follow up. Additional Supportive Information: The patient received only the AS01B adjuvant of Shingrix. It was administered prior to reconstitution, which led to inappropriate preparation of medication and Inappropriate dose of vaccine administered.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1747640

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 3n3gh

gering
Staat
CA
Alter
-
Geschlecht
F
Eingang
30.09.2021
Impfdatum
-
Beginn
-
Tage bis Beginn
-
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered Product preparation issue

Symptomtext

was given 2 portion of the liquid adjuvant only; was given 2 portion of the liquid adjuvant only; This case was reported by a nurse via call center representative and described the occurrence of inappropriate dose of vaccine administered in a 56-year-old female patient who received Herpes zoster (Shingrix) (batch number 3n3gh, expiry date 28th January 2023) for prophylaxis. On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced inappropriate dose of vaccine administered and inappropriate preparation of medication. On an unknown date, the outcome of the inappropriate dose of vaccine administered and inappropriate preparation of medication were unknown. Additional details were provided as follows: The nurse reported that, the patient was given 2 portion of the liquid adjuvant of shignrix only, which led to inappropriate dose of vaccine administered and inappropriate preparation of medication. The reporter consented to follow up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1710751

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 3N3GH

gering
Staat
TX
Alter
56,0
Geschlecht
F
Eingang
18.09.2021
Impfdatum
-
Beginn
10.09.2021
Tage bis Beginn
-
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered Product preparation issue

Symptomtext

Administered without antigen; Administered without antigen; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 56-year-old female patient who received Herpes zoster (Shingrix) (batch number 9DM72, expiry date 28th January 2023) and (batch number 3N3GH, expiry date 28th January 2023) for prophylaxis. On 10th September 2021, the patient received the 2nd dose of Shingrix (intramuscular) 1 ml. On an unknown date, the dose was an unknown dose. On 10th September 2021, unknown after receiving Shingrix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. Additional details were provided as follows: The patient was administered 1 ml of adjuvant in the left deltoid. The medical assistant reported that, 2 vials of Shingrix adjuvant (batch number 3N3GH) were administered to the patient without active component (antigen), which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The reporter gave a consent to follow-up with health care professional office.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1594241

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 3N3GH

gering
Staat
CA
Alter
54,0
Geschlecht
F
Eingang
21.08.2021
Impfdatum
21.07.2021
Beginn
21.07.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered Product preparation issue

Symptomtext

Patient received only the liquid adjuvant; Patient received only the liquid adjuvant; This case was reported by a physician via call center representative and described the occurrence of inappropriate preparation of medication in a 54-year-old female patient who received Herpes zoster (Shingrix) (batch number 3N3GH, expiry date 28th January 2023) for prophylaxis. On 21st July 2021, the patient received the 1st dose of Shingrix (intramuscular). On 21st July 2021, unknown after receiving Shingrix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. Additional details were provided are as follows: The patient received only the liquid adjuvant of Shingrix intramuscularly without the active component, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The lot number of the powder vial in the box (which was not administered) was 75xa2, expiration date 28th January 2023. The reporter consented to follow-up. The case has been linked with case US2021171382 reported by same reporter.; Sender's Comments: US-GLAXOSMITHKLINE-US2021171382:Same reporter.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1594240

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 3N3GH

gering
Staat
CA
Alter
58,0
Geschlecht
F
Eingang
21.08.2021
Impfdatum
14.07.2021
Beginn
14.07.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered Product preparation issue

Symptomtext

Patient received only the liquid adjuvant; Patient received only the liquid adjuvant; This case was reported by a physician via call center representative and described the occurrence of inappropriate preparation of medication in a 58-year-old female patient who received Herpes zoster (Shingrix) (batch number 3N3GH, expiry date 28th January 2023) for prophylaxis. On 14th July 2021, the patient received the 1st dose of Shingrix (intramuscular). On 14th July 2021, unknown after receiving Shingrix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. Additional details were provided are as follows: The reporter was the doctor. The patient received only the liquid adjuvant of Shingrix intramuscularly without the active component, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The lot number of the powder vial in the box (which was not administered) was 75xa2, expiration date 28th January 2023. The reporter consented to follow-up. This case has been linked with case US2021171383, reported by the same reporter; Sender's Comments: US-GLAXOSMITHKLINE-US2021171383:Same reporter.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1394007

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 3N3GH

gering
Staat
MD
Alter
-
Geschlecht
U
Eingang
12.06.2021
Impfdatum
09.06.2021
Beginn
09.06.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered Product preparation issue

Symptomtext

Patient was given only the adjuvant portion; Patient was given only the adjuvant portion; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Herpes zoster (Shingrix) (batch number 3N3GH, expiry date 28th January 2023) for prophylaxis. On 9th June 2021, the patient received Shingrix (unknown). On 9th June 2021, unknown after receiving Shingrix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. Additional details were provided as follows: Age at vaccination was not reported. The patient was given only the adjuvant portion of Shingrix, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The reporter had no patient information at hand at time of the call. The reporter consented to follow up but agreed to follow-up via postal mail. The reported batch number pertains to Shingrix adjuvant.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-